• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2
Antiviral Res. 2023 Jul 19:105677. doi: 10.1016/j.antiviral.2023.105677. Online ahead of print.ABSTRACTSevere Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a respiratory virus that causes COVID-19 disease, with an estimated global mortality of approximately 2%. While global response strategies, which are predominantly reliant on regular vaccinations, have shifted from zero COVID to living with COVID, there is a distinct lack of broad-spectrum direct acting antiviral therapies that maintain efficacy across evolving SARS-CoV-2 variants of concern. This is of most concern for immunocompromised and immunosuppressed ...
Source: Antiviral Research - July 21, 2023 Category: Virology Authors: Ellen Bowden-Reid Scott Ledger Yuan Zhang Francesca Di Giallonardo Anupriya Aggarwal Alberto Ospina Stella Anouschka Akerman Vanessa Milogiannakis Gregory Walker William Rawlinson Stuart Turville Anthony D Kelleher Chantelle Ahlenstiel Source Type: research

Inflammasomes during SARS-CoV-2 infection and development of their corresponding inhibitors
Corona Virus Disease 2019 (COVID-19) continues to be a burden for human health since its outbreak in Wuhan, China in December 2019. Recently, the emergence of new variants of concerns (VOCs) is challenging for vaccines and drugs efficiency. In severe cases, SARS-CoV-2 provokes inappropriate hyperinflammatory immune responses leading to acute respiratory distress syndrome (ARDS) and even death. This process is regulated by inflammasomes which are activated after binding of the viral spike (S) protein to cellular angiotensin-converting enzyme 2 (ACE2) receptor and triggers innate immune responses. Therefore, the formation of...
Source: Frontiers in cellular and infection microbiology - June 9, 2023 Category: Microbiology Source Type: research

Viruses, Vol. 15, Pages 100: RNA Interference Approach Is a Good Strategy against SARS-CoV-2
ng-Huang Shen COVID-19, caused by SARS-CoV-2, created a devastating outbreak worldwide and consequently became a global health concern. However, no verifiable, specifically targeted treatment has been devised for COVID-19. Several emerging vaccines have been used, but protection has not been satisfactory. The complex genetic composition and high mutation frequency of SARS‑CoV‑2 have caused an uncertain vaccine response. Small interfering RNA (siRNA)-based therapy is an efficient strategy to control various infectious diseases employing post-transcriptional gene silencing through the silencin...
Source: Viruses - December 29, 2022 Category: Virology Authors: Ying-Ray Lee Huey-Pin Tsai Chun-Sheng Yeh Chiung-Yao Fang Michael W. Y. Chan Tzu-Yun Wu Cheng-Huang Shen Tags: Article Source Type: research

Genes, Vol. 13, Pages 2147: Anticipating the Next Chess Move: Blocking SARS-CoV-2 Replication and Simultaneously Disarming Viral Escape Mechanisms
Assumpção The COVID-19 pandemic initiated a race to determine the best measures to control the disease and to save as many people as possible. Efforts to implement social distancing, the use of masks, and massive vaccination programs turned out to be essential in reducing the devastating effects of the pandemic. Nevertheless, the high mutation rates of SARS-CoV-2 challenge the vaccination strategy and maintain the threat of new outbreaks due to the risk of infection surges and even lethal variations able to resist the effects of vaccines and upset the balance. Most of the new therapies tested against SARS-CoV-2 came ...
Source: Genes - November 18, 2022 Category: Genetics & Stem Cells Authors: Samir Mansour Moraes Casseb Andr é Salim Khayat Jorge Estefano Santana de Souza Edivaldo Herculano Correa de Oliveira Sidney Emanuel Batista Dos Santos Pedro Fernando da Costa Vasconcelos Paulo Pimentel de Assump ção Tags: Article Source Type: research

Recent advances on therapeutic potentials of gold and silver nanobiomaterials for human viral diseases
Curr Res Chem Biol. 2022;2:100021. doi: 10.1016/j.crchbi.2022.100021. Epub 2022 Feb 1.ABSTRACTViral diseases are prominent among the widely spread infections threatening human well-being. Real-life clinical successes of the few available therapeutics are challenged by pathogenic resistance and suboptimal delivery to target sites. Nanotechnology has aided the design of functionalised and non-functionalised Au and Ag nanobiomaterials through physical, chemical and biological (green synthesis) methods with improved antiviral efficacy and delivery. In this review, innovative designs as well as interesting antiviral activities ...
Source: Herpes - July 11, 2022 Category: Infectious Diseases Authors: Yusuf Oloruntoyin Ayipo Ajibola Abdulahi Bakare Umar Muhammad Badeggi Akeem Adebayo Jimoh Amudat Lawal Mohd Nizam Mordi Source Type: research

Abstracts of Presentations at the Association of Clinical Scientists 143 < sup > rd < /sup > Meeting Louisville, KY May 11-14,2022
Conclusion: These assays are suitable for routine diagnostic. The UltraFast NextGenPCR is the fastest with average time (30mins), followed by Agilent (2 hrs) and MassArray (6hrs). Upon completion of this activity, participants should be able to examine, measure and compare results from different assays for SARS detection, evaluate and diagnose accurately, as well as being able to plan, organize and recommend a diagnostic procedure for diagnostic laboratory. Key words: SARS-CoV-2, RNA extraction, RT-PCR, limit of detection, quantification cycle, COVID-19, in vitro diagnostic tests, Agilent, Massarray, Ultrafast. [20] From t...
Source: Annals of Clinical and Laboratory Science - July 1, 2022 Category: Laboratory Medicine Source Type: research

Pages: 1  2  3